Tirzepatide is Associated With Reduced Risk of Primary Open-Angle Glaucoma and Ocular Hypertension in Patients With Type 2 Diabetes.
Hong Alexander T, Lin Forest, Baxter Sally, Weinreb Robert N
Tirzepatide significantly reduced primary open-angle glaucoma, ocular hypertension, and glaucoma treatment risk in type 2 diabetes patients. This suggests a potential neuroprotective or pressure-lowering benefit, offering a novel therapeutic avenue for glaucoma management.